🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Huge thanks to Shahla Bari MD for the invitation to Duke Cancer to discuss the #microbiome in #kidneycancer. I'll be highlighting work from my terrific team (Nazli Dizman Hedyeh Ebrahimi Regina Barragan-Carrillo @luismezaco et al) & also some of the pioneering studies led by Bertrand Routy MD,PhD

Brilliant minds coming together at Duke’s 1st Kidney cancer & microbiome symposium. Special thanks to Sumanta K. Pal, MD, FASCO William Y. Kim Jose Conejo-Garcia Dan George Andrew Armstrong Jen-Tsan Ashley Chi #RamprasadSrinivasan DCI Center for Prostate & Urologic Cancers Duke Microbiome Center

Tivumecirnon Plus Pembrolizumab Displays Activity and Tolerability in HNSCC Jameel Muzaffar MD Duke Cancer Duke University School of Medicine #hncsm onclive.com/view/tivumecir…

Amazing talk from Oliver Sartor Mayo Clinic - a wonderful overview of multiple practice-changing trials (& forthcoming studies!) related to #radioligand tx & #novelimaging in #prostatecancer! We will have to have you back in person soon! Tanya Dorff Alex Chehrazi-Raffle, MD Abhishek Tripathi

Thanks for organizing Shahla Bari MD. Microbiome research is taking off for many cancer types, but especially Kidney Cancer. Come hear more. Or just come to hang out with DCI Center for Prostate & Urologic Cancers and have lunch.

Welcome to the Duke GUrus, Dillon! Excited to have you join the DCI Center for Prostate & Urologic Cancers fam!

Duke Microbiome in oncology symposium #2. Supported by Steven Patierno, PhD Dan George Raphael Valdivia Duke Microbiome Center The greatest minds in microbiome #GeorgioTrienchieri Ting Lab Tessa Andermann Melody Smith, MD, MS #Jobinlab Humaira Sarfraz Sumanta K. Pal, MD, FASCO

Presentation of new DFF332, some evidence of clinical efficacy, perhaps less anemia and no hypoxia, but optimal dose not yet identified Sumanta K. Pal, MD, FASCO Laurence Albiges #ASCO24

Elated to discuss the role of microbiome and metabolome in kidney cancer. Thank you Conquer Cancer, the ASCO Foundation for the opportunity. DCI Center for Prostate & Urologic Cancers Duke Cancer #womeninoncology #womeninGU

Dr. Tannir continuing his legacy by supporting young investigators with “Nizar Tannir Endowed Merit Award”. Let’s give him a standing ovation #NizarTannir MD Anderson Cancer Center

Huge congrats to #NizarTannirMD MD Anderson Cancer Center who drove forward this impt trial (#PIVOT09) comparing pegylated #IL2/#nivolumab to #TKI; was a privelege to work w him & others (Maria Nirvana Formiga, MD, PhD Neeraj Agarwal, MD, FASCO Dan George) on this trial now in Journal of Clinical Oncology. PFS & OS no different;

Saying goodbye to our lab [email protected] , wishing him success as an IM resident . Welcoming our new rockstar AnnaLong and celebrating our current research team-Amit Sen and Mitu Saha MD .

DCI Center for Prostate and Urologic Cancers is tackling #CancerDisparities in #ProstateCancer. Watch #ASCO2024 clip to see how the #PantherTrial showed surprising survival for Black men specifically. More studies in progress. Dan George American Cancer Society Prostate Cancer Foundation Duke Health

It's with great pleasure that I share with you our paper evaluating #cabozantinib with #nivolumab +/- #CBM588 in pts with advanced #kidneycancer, published today in Nature Medicine! 🙏Huge thanks 1st/foremost to patients & their families. Had tons of support from the amazing

Congrats Hedyeh , Dr. Pal and team. This is such a great achievement at such an early part of your life, Hedyeh. This is not only a testament to your hard work and relentless drive , but also the brilliance and nurturing environment that Dr. Pal offers to his team.

Another incredible accomplishment by Sumanta K. Pal, MD, FASCO and his extraordinary team of young trainees! Luis A. Meza Nazli Dizman Yale IM Traditional Residency Program Yale Internal Medicine Smilow Cancer Hospital

#KCRS24 Rapid Abstract: Renee Maria Saliby Dana-Farber studies intermediate endpoints for OS in metastatic RCC treated with ICIs. Time to Next Therapy (TTNT) is a strong predictor of survival. Abstract Book: bit.ly/KCRS24Abstracts Register: kcrs.kidneycan.org

#KCRS24 Session 7 featured our oral abstract presentations! Belzutifan v Everolimus Laurence Albiges Belzutifan Safety Profile Toni Choueiri, MD CDK4/6 Inhibition Bradley McGregor IL7 SNP, Adverse Events Eddy Saad Liquid Biopsy DNA Analysis Karl Semaan, MD, MSc Gut Microbiome & ICI Combos Nazli Dizman

So excited to see my colleague’s brilliant work. Your team leads the field in probiotics and microbiome in RCC. Looking forward to phase III.

🎤 Don't miss our latest roundtable featuring Laurence Albiges, Renee Maria Saliby, Tian Zhang, MD, MHS, and Shahla Bari MD discussing the risk stratification and management of metastatic #nccRCC. 👀 Watch Here: buff.ly/46jG3e9